Financialsexperimental
Protalix BioTherapeutics, Inc. (PLX). Every figure is as filed in the company's 10-Q and 10-K reports. Quarters a filing does not report on their own are worked out from its year-to-date figures and marked *.
USD in thousands · shares (whole numbers) · per-share amounts in USD
| Income Statement | FY FY25 31 Dec 2025 | FY FY24 31 Dec 2024 | FY FY23 31 Dec 2023 | FY FY22 31 Dec 2022 | FY FY21 31 Dec 2021 |
|---|---|---|---|---|---|
| TOTAL REVENUE | 52,744 | 53,399 | 65,494 | 47,638 | 38,350 |
| COST OF REVENUES | -26,993 | -24,319 | -22,982 | -19,592 | -16,349 |
| RESEARCH AND DEVELOPMENT EXPENSES, NET | -19,569 | -12,970 | -17,093 | -29,349 | -29,734 |
| SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES | -11,682 | -12,193 | -14,959 | -11,711 | -12,729 |
| OPERATING INCOME (LOSS) | -5,500 | 3,917 | 10,460 | -13,014 | -20,462 |
| FINANCIAL EXPENSES | -1,062 | -3,180 | -2,529 | -7,521 | |
| FINANCIAL EXPENSES | -1,191 | ||||
| FINANCIAL INCOME | 1,083 | 1,299 | 1,286 | 1,146 | 401 |
| FINANCIAL INCOME (EXPENSES), NET | -108 | 237 | -1,894 | -1,383 | -7,120 |
| INCOME (LOSS) BEFORE TAXES ON INCOME | -5,608 | 4,154 | 8,566 | -14,397 | |
| TAXES ON INCOME | 996 | 1,222 | 254 | 530 | |
| NET INCOME (LOSS) | -6,604 | 2,932 | 8,312 | -14,927 | -27,582 |
| EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share) | -0.08 | 0.04 | 0.12 | -0.31 | -0.62 |
| EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share) | -0.08 | 0.04 | 0.09 | -0.31 | -0.62 |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares) | 78,546,234 | 72,530,698 | 67,512,527 | 48,472,159 | 44,140,233 |
| WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares) | 78,546,234 | 81,057,176 | 82,424,016 | 48,472,159 | 44,140,233 |
| TOTAL REVENUE — Product | 51,802 | 52,981 | 40,418 | 25,292 | 16,749 |
| TOTAL REVENUE — License And Service | 942 | 418 | 25,076 | 22,346 | 21,601 |